Xilis, Inc is a Duke spinoff founded by Duke professors David Hsu (M.D./Ph.D) and Xiling Shen (Ph.D) in Durham, North Carolina. The company has been developing cutting-edge Patient-Derived Micro-OrganoSpheres (MOS) technology for precision cancer diagnostics and drug development. Xilis’ transformative platform recreates patient-specific tumors in their 3D and environmental complexity at micro-scale ex vivo, allowing ultra-high-throughput, clinically-relevant, and affordable experimental selection of the safest, most effective drugs for each and every patient in a matter of days. The company aims to transform cancer care by ensuring each and every patient gets treated in a timely manner with the single most appropriate drug available to them. We are supported in this mission by top Silicon Valley and New York venture firms that are leaders in the healthcare space and have invested in top precision medicine companies including Foundation Medicine and Guardant Health.  Role\ Apply now and work remotely at Xilis, Inc.